nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—ORM1—Vemurafenib—melanoma	0.19	0.288	CbGbCtD
Propranolol—ABCB1—melanoma	0.159	1	CbGaD
Propranolol—CYP1A1—Dacarbazine—melanoma	0.0819	0.125	CbGbCtD
Propranolol—CYP1A2—Carmustine—melanoma	0.0604	0.0918	CbGbCtD
Propranolol—CYP1A2—Vemurafenib—melanoma	0.0477	0.0726	CbGbCtD
Propranolol—CYP3A4—Temozolomide—melanoma	0.0456	0.0694	CbGbCtD
Propranolol—CYP2D6—Vemurafenib—melanoma	0.0393	0.0598	CbGbCtD
Propranolol—CYP1A2—Dacarbazine—melanoma	0.0366	0.0556	CbGbCtD
Propranolol—CYP3A7—Docetaxel—melanoma	0.0293	0.0446	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Docetaxel—melanoma	0.0293	0.0446	CbGbCtD
Propranolol—ABCB1—Dactinomycin—melanoma	0.0277	0.0422	CbGbCtD
Propranolol—CYP3A4—Vemurafenib—melanoma	0.025	0.038	CbGbCtD
Propranolol—CYP3A5—Docetaxel—melanoma	0.022	0.0335	CbGbCtD
Propranolol—ABCB1—Docetaxel—melanoma	0.0143	0.0218	CbGbCtD
Propranolol—CYP3A4—Docetaxel—melanoma	0.00858	0.013	CbGbCtD
Propranolol—Colitis ischaemic—Docetaxel—melanoma	0.00221	0.0242	CcSEcCtD
Propranolol—Lower respiratory tract infection—Docetaxel—melanoma	0.0019	0.0209	CcSEcCtD
Propranolol—Myopathy—Temozolomide—melanoma	0.0014	0.0153	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Vemurafenib—melanoma	0.00125	0.0137	CcSEcCtD
Propranolol—Systemic lupus erythematosus—Docetaxel—melanoma	0.00118	0.0129	CcSEcCtD
Propranolol—Carvedilol—HIF1A—melanoma	0.0011	0.463	CrCbGaD
Propranolol—Infestation NOS—Vemurafenib—melanoma	0.00107	0.0117	CcSEcCtD
Propranolol—Infestation—Vemurafenib—melanoma	0.00107	0.0117	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.00106	0.0116	CcSEcCtD
Propranolol—Disorientation—Bleomycin—melanoma	0.000941	0.0103	CcSEcCtD
Propranolol—Erythema multiforme—Vemurafenib—melanoma	0.000909	0.00995	CcSEcCtD
Propranolol—Dry eye—Temozolomide—melanoma	0.000904	0.00989	CcSEcCtD
Propranolol—Throat sore—Docetaxel—melanoma	0.000903	0.00988	CcSEcCtD
Propranolol—Oropharyngeal discomfort—Docetaxel—melanoma	0.000895	0.00979	CcSEcCtD
Propranolol—Cardiac disorder—Vemurafenib—melanoma	0.000892	0.00977	CcSEcCtD
Propranolol—Rash erythematous—Docetaxel—melanoma	0.00085	0.0093	CcSEcCtD
Propranolol—Alopecia—Vemurafenib—melanoma	0.00085	0.0093	CcSEcCtD
Propranolol—Erythema—Vemurafenib—melanoma	0.000837	0.00916	CcSEcCtD
Propranolol—Lethargy—Dactinomycin—melanoma	0.000801	0.00877	CcSEcCtD
Propranolol—Vascular purpura—Temozolomide—melanoma	0.000794	0.00869	CcSEcCtD
Propranolol—Amnesia—Carmustine—melanoma	0.000782	0.00856	CcSEcCtD
Propranolol—Amnesia—Temozolomide—melanoma	0.000756	0.00828	CcSEcCtD
Propranolol—Dermatitis exfoliative—Temozolomide—melanoma	0.000753	0.00824	CcSEcCtD
Propranolol—Purpura—Temozolomide—melanoma	0.000737	0.00807	CcSEcCtD
Propranolol—Cough—Vemurafenib—melanoma	0.00073	0.008	CcSEcCtD
Propranolol—Bronchospasm—Bleomycin—melanoma	0.000716	0.00784	CcSEcCtD
Propranolol—Oropharyngeal pain—Docetaxel—melanoma	0.000716	0.00783	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.000708	0.00775	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.000707	0.00774	CcSEcCtD
Propranolol—Affect lability—Temozolomide—melanoma	0.000699	0.00765	CcSEcCtD
Propranolol—Anaphylactic shock—Vemurafenib—melanoma	0.000683	0.00748	CcSEcCtD
Propranolol—Infection—Vemurafenib—melanoma	0.000679	0.00743	CcSEcCtD
Propranolol—Mood swings—Temozolomide—melanoma	0.000673	0.00737	CcSEcCtD
Propranolol—Nervous system disorder—Vemurafenib—melanoma	0.00067	0.00733	CcSEcCtD
Propranolol—Skin disorder—Vemurafenib—melanoma	0.000663	0.00726	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Temozolomide—melanoma	0.00064	0.007	CcSEcCtD
Propranolol—Neutropenia—Dactinomycin—melanoma	0.000635	0.00695	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.0006	0.00657	CcSEcCtD
Propranolol—Neutropenia—Carmustine—melanoma	0.000594	0.0065	CcSEcCtD
Propranolol—Decreased appetite—Vemurafenib—melanoma	0.000594	0.0065	CcSEcCtD
Propranolol—Bronchitis—Temozolomide—melanoma	0.00059	0.00646	CcSEcCtD
Propranolol—Gastrointestinal disorder—Vemurafenib—melanoma	0.00059	0.00646	CcSEcCtD
Propranolol—Fatigue—Vemurafenib—melanoma	0.000589	0.00645	CcSEcCtD
Propranolol—Constipation—Vemurafenib—melanoma	0.000584	0.00639	CcSEcCtD
Propranolol—Lightheadedness—Docetaxel—melanoma	0.000582	0.00637	CcSEcCtD
Propranolol—Neutropenia—Temozolomide—melanoma	0.000574	0.00628	CcSEcCtD
Propranolol—Erectile dysfunction—Temozolomide—melanoma	0.000565	0.00619	CcSEcCtD
Propranolol—Depression—Carmustine—melanoma	0.000565	0.00618	CcSEcCtD
Propranolol—Agranulocytosis—Dactinomycin—melanoma	0.000565	0.00618	CcSEcCtD
Propranolol—Infestation—Temozolomide—melanoma	0.000547	0.00599	CcSEcCtD
Propranolol—Infestation NOS—Temozolomide—melanoma	0.000547	0.00599	CcSEcCtD
Propranolol—Depression—Temozolomide—melanoma	0.000546	0.00597	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Temozolomide—melanoma	0.000543	0.00594	CcSEcCtD
Propranolol—Body temperature increased—Vemurafenib—melanoma	0.00054	0.00591	CcSEcCtD
Propranolol—Pharyngitis—Dactinomycin—melanoma	0.000539	0.0059	CcSEcCtD
Propranolol—Cardiac failure congestive—Docetaxel—melanoma	0.000521	0.0057	CcSEcCtD
Propranolol—Alopecia—Bleomycin—melanoma	0.000515	0.00563	CcSEcCtD
Propranolol—Erythema multiforme—Dactinomycin—melanoma	0.000514	0.00562	CcSEcCtD
Propranolol—Erythema—Bleomycin—melanoma	0.000507	0.00555	CcSEcCtD
Propranolol—Hallucination—Carmustine—melanoma	0.000506	0.00554	CcSEcCtD
Propranolol—Hypersensitivity—Vemurafenib—melanoma	0.000503	0.00551	CcSEcCtD
Propranolol—Visual disturbance—Docetaxel—melanoma	0.000498	0.00546	CcSEcCtD
Propranolol—Asthenia—Vemurafenib—melanoma	0.00049	0.00537	CcSEcCtD
Propranolol—Visual impairment—Carmustine—melanoma	0.00049	0.00536	CcSEcCtD
Propranolol—Hallucination—Temozolomide—melanoma	0.000489	0.00535	CcSEcCtD
Propranolol—Pharyngitis—Temozolomide—melanoma	0.000488	0.00534	CcSEcCtD
Propranolol—Lethargy—Docetaxel—melanoma	0.000482	0.00528	CcSEcCtD
Propranolol—Alopecia—Dactinomycin—melanoma	0.00048	0.00526	CcSEcCtD
Propranolol—Visual impairment—Temozolomide—melanoma	0.000473	0.00518	CcSEcCtD
Propranolol—Erythema—Dactinomycin—melanoma	0.000473	0.00518	CcSEcCtD
Propranolol—Diarrhoea—Vemurafenib—melanoma	0.000467	0.00512	CcSEcCtD
Propranolol—Erythema multiforme—Temozolomide—melanoma	0.000465	0.00509	CcSEcCtD
Propranolol—Cardiac disorder—Temozolomide—melanoma	0.000456	0.00499	CcSEcCtD
Propranolol—Dizziness—Vemurafenib—melanoma	0.000452	0.00494	CcSEcCtD
Propranolol—Alopecia—Carmustine—melanoma	0.000449	0.00492	CcSEcCtD
Propranolol—Mental disorder—Carmustine—melanoma	0.000445	0.00488	CcSEcCtD
Propranolol—Carvedilol—VEGFA—melanoma	0.000445	0.186	CrCbGaD
Propranolol—Erythema—Carmustine—melanoma	0.000443	0.00485	CcSEcCtD
Propranolol—Cough—Bleomycin—melanoma	0.000442	0.00484	CcSEcCtD
Propranolol—Vomiting—Vemurafenib—melanoma	0.000434	0.00475	CcSEcCtD
Propranolol—Alopecia—Temozolomide—melanoma	0.000434	0.00475	CcSEcCtD
Propranolol—Rash—Vemurafenib—melanoma	0.000431	0.00471	CcSEcCtD
Propranolol—Mental disorder—Temozolomide—melanoma	0.00043	0.00471	CcSEcCtD
Propranolol—Dermatitis—Vemurafenib—melanoma	0.00043	0.00471	CcSEcCtD
Propranolol—Erythema—Temozolomide—melanoma	0.000428	0.00468	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Docetaxel—melanoma	0.000425	0.00466	CcSEcCtD
Propranolol—Anaphylactic shock—Bleomycin—melanoma	0.000414	0.00453	CcSEcCtD
Propranolol—Infection—Bleomycin—melanoma	0.000411	0.0045	CcSEcCtD
Propranolol—Agitation—Carmustine—melanoma	0.000407	0.00445	CcSEcCtD
Propranolol—Nausea—Vemurafenib—melanoma	0.000406	0.00444	CcSEcCtD
Propranolol—Bronchospasm—Docetaxel—melanoma	0.000402	0.0044	CcSEcCtD
Propranolol—Agitation—Temozolomide—melanoma	0.000393	0.0043	CcSEcCtD
Propranolol—Vertigo—Temozolomide—melanoma	0.000384	0.00421	CcSEcCtD
Propranolol—Convulsion—Carmustine—melanoma	0.000383	0.0042	CcSEcCtD
Propranolol—Infection—Dactinomycin—melanoma	0.000383	0.0042	CcSEcCtD
Propranolol—Neutropenia—Docetaxel—melanoma	0.000382	0.00418	CcSEcCtD
Propranolol—Cough—Temozolomide—melanoma	0.000373	0.00409	CcSEcCtD
Propranolol—Paraesthesia—Bleomycin—melanoma	0.000372	0.00407	CcSEcCtD
Propranolol—Convulsion—Temozolomide—melanoma	0.000371	0.00406	CcSEcCtD
Propranolol—Dyspnoea—Bleomycin—melanoma	0.000369	0.00404	CcSEcCtD
Propranolol—Infestation NOS—Docetaxel—melanoma	0.000364	0.00398	CcSEcCtD
Propranolol—Infestation—Docetaxel—melanoma	0.000364	0.00398	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000362	0.00396	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000361	0.00395	CcSEcCtD
Propranolol—Decreased appetite—Bleomycin—melanoma	0.00036	0.00394	CcSEcCtD
Propranolol—Infection—Carmustine—melanoma	0.000359	0.00393	CcSEcCtD
Propranolol—Pain—Bleomycin—melanoma	0.000354	0.00387	CcSEcCtD
Propranolol—Anaphylactic shock—Temozolomide—melanoma	0.000349	0.00382	CcSEcCtD
Propranolol—Infection—Temozolomide—melanoma	0.000347	0.0038	CcSEcCtD
Propranolol—Nervous system disorder—Temozolomide—melanoma	0.000342	0.00375	CcSEcCtD
Propranolol—Agranulocytosis—Docetaxel—melanoma	0.00034	0.00372	CcSEcCtD
Propranolol—Skin disorder—Temozolomide—melanoma	0.000339	0.00371	CcSEcCtD
Propranolol—Decreased appetite—Dactinomycin—melanoma	0.000335	0.00367	CcSEcCtD
Propranolol—Fatigue—Dactinomycin—melanoma	0.000333	0.00364	CcSEcCtD
Propranolol—Pain—Dactinomycin—melanoma	0.00033	0.00361	CcSEcCtD
Propranolol—Urticaria—Bleomycin—melanoma	0.000329	0.0036	CcSEcCtD
Propranolol—Body temperature increased—Bleomycin—melanoma	0.000327	0.00358	CcSEcCtD
Propranolol—Insomnia—Carmustine—melanoma	0.000327	0.00358	CcSEcCtD
Propranolol—Paraesthesia—Carmustine—melanoma	0.000324	0.00355	CcSEcCtD
Propranolol—Pharyngitis—Docetaxel—melanoma	0.000324	0.00355	CcSEcCtD
Propranolol—Dyspnoea—Carmustine—melanoma	0.000322	0.00353	CcSEcCtD
Propranolol—Somnolence—Carmustine—melanoma	0.000321	0.00352	CcSEcCtD
Propranolol—Insomnia—Temozolomide—melanoma	0.000316	0.00346	CcSEcCtD
Propranolol—Gastrointestinal pain—Dactinomycin—melanoma	0.000316	0.00346	CcSEcCtD
Propranolol—Visual impairment—Docetaxel—melanoma	0.000315	0.00345	CcSEcCtD
Propranolol—Decreased appetite—Carmustine—melanoma	0.000314	0.00344	CcSEcCtD
Propranolol—Paraesthesia—Temozolomide—melanoma	0.000313	0.00343	CcSEcCtD
Propranolol—Gastrointestinal disorder—Carmustine—melanoma	0.000312	0.00341	CcSEcCtD
Propranolol—Dyspnoea—Temozolomide—melanoma	0.000311	0.00341	CcSEcCtD
Propranolol—Somnolence—Temozolomide—melanoma	0.00031	0.0034	CcSEcCtD
Propranolol—Erythema multiforme—Docetaxel—melanoma	0.000309	0.00338	CcSEcCtD
Propranolol—Pain—Carmustine—melanoma	0.000309	0.00338	CcSEcCtD
Propranolol—Constipation—Carmustine—melanoma	0.000309	0.00338	CcSEcCtD
Propranolol—Dyspepsia—Temozolomide—melanoma	0.000307	0.00336	CcSEcCtD
Propranolol—Abdominal pain—Dactinomycin—melanoma	0.000305	0.00334	CcSEcCtD
Propranolol—Body temperature increased—Dactinomycin—melanoma	0.000305	0.00334	CcSEcCtD
Propranolol—Hypersensitivity—Bleomycin—melanoma	0.000305	0.00334	CcSEcCtD
Propranolol—Decreased appetite—Temozolomide—melanoma	0.000303	0.00332	CcSEcCtD
Propranolol—Cardiac disorder—Docetaxel—melanoma	0.000303	0.00332	CcSEcCtD
Propranolol—Gastrointestinal disorder—Temozolomide—melanoma	0.000301	0.0033	CcSEcCtD
Propranolol—Fatigue—Temozolomide—melanoma	0.000301	0.00329	CcSEcCtD
Propranolol—Constipation—Temozolomide—melanoma	0.000299	0.00327	CcSEcCtD
Propranolol—Pain—Temozolomide—melanoma	0.000299	0.00327	CcSEcCtD
Propranolol—Asthenia—Bleomycin—melanoma	0.000297	0.00325	CcSEcCtD
Propranolol—Gastrointestinal pain—Carmustine—melanoma	0.000295	0.00323	CcSEcCtD
Propranolol—Alopecia—Docetaxel—melanoma	0.000289	0.00316	CcSEcCtD
Propranolol—Mental disorder—Docetaxel—melanoma	0.000286	0.00313	CcSEcCtD
Propranolol—Body temperature increased—Carmustine—melanoma	0.000286	0.00313	CcSEcCtD
Propranolol—Abdominal pain—Carmustine—melanoma	0.000286	0.00313	CcSEcCtD
Propranolol—Gastrointestinal pain—Temozolomide—melanoma	0.000285	0.00313	CcSEcCtD
Propranolol—Erythema—Docetaxel—melanoma	0.000284	0.00311	CcSEcCtD
Propranolol—Hypersensitivity—Dactinomycin—melanoma	0.000284	0.00311	CcSEcCtD
Propranolol—Urticaria—Temozolomide—melanoma	0.000277	0.00304	CcSEcCtD
Propranolol—Asthenia—Dactinomycin—melanoma	0.000277	0.00303	CcSEcCtD
Propranolol—Abdominal pain—Temozolomide—melanoma	0.000276	0.00302	CcSEcCtD
Propranolol—Body temperature increased—Temozolomide—melanoma	0.000276	0.00302	CcSEcCtD
Propranolol—Hypersensitivity—Carmustine—melanoma	0.000266	0.00291	CcSEcCtD
Propranolol—Diarrhoea—Dactinomycin—melanoma	0.000264	0.00289	CcSEcCtD
Propranolol—Vomiting—Bleomycin—melanoma	0.000263	0.00288	CcSEcCtD
Propranolol—Rash—Bleomycin—melanoma	0.000261	0.00286	CcSEcCtD
Propranolol—Dermatitis—Bleomycin—melanoma	0.000261	0.00285	CcSEcCtD
Propranolol—Asthenia—Carmustine—melanoma	0.000259	0.00284	CcSEcCtD
Propranolol—Hypersensitivity—Temozolomide—melanoma	0.000257	0.00282	CcSEcCtD
Propranolol—Asthenia—Temozolomide—melanoma	0.00025	0.00274	CcSEcCtD
Propranolol—Cough—Docetaxel—melanoma	0.000248	0.00272	CcSEcCtD
Propranolol—Diarrhoea—Carmustine—melanoma	0.000247	0.00271	CcSEcCtD
Propranolol—Convulsion—Docetaxel—melanoma	0.000246	0.0027	CcSEcCtD
Propranolol—Nausea—Bleomycin—melanoma	0.000246	0.00269	CcSEcCtD
Propranolol—Vomiting—Dactinomycin—melanoma	0.000245	0.00269	CcSEcCtD
Propranolol—Rash—Dactinomycin—melanoma	0.000243	0.00266	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00024	0.00263	CcSEcCtD
Propranolol—Dizziness—Carmustine—melanoma	0.000239	0.00262	CcSEcCtD
Propranolol—Diarrhoea—Temozolomide—melanoma	0.000239	0.00261	CcSEcCtD
Propranolol—Anaphylactic shock—Docetaxel—melanoma	0.000232	0.00254	CcSEcCtD
Propranolol—Dizziness—Temozolomide—melanoma	0.000231	0.00253	CcSEcCtD
Propranolol—Infection—Docetaxel—melanoma	0.000231	0.00252	CcSEcCtD
Propranolol—Vomiting—Carmustine—melanoma	0.00023	0.00251	CcSEcCtD
Propranolol—Nausea—Dactinomycin—melanoma	0.000229	0.00251	CcSEcCtD
Propranolol—Rash—Carmustine—melanoma	0.000228	0.00249	CcSEcCtD
Propranolol—Nervous system disorder—Docetaxel—melanoma	0.000228	0.00249	CcSEcCtD
Propranolol—Dermatitis—Carmustine—melanoma	0.000228	0.00249	CcSEcCtD
Propranolol—Skin disorder—Docetaxel—melanoma	0.000225	0.00247	CcSEcCtD
Propranolol—Vomiting—Temozolomide—melanoma	0.000222	0.00243	CcSEcCtD
Propranolol—Atenolol—ABCB1—melanoma	0.000221	0.0925	CrCbGaD
Propranolol—Rash—Temozolomide—melanoma	0.00022	0.00241	CcSEcCtD
Propranolol—Dermatitis—Temozolomide—melanoma	0.00022	0.00241	CcSEcCtD
Propranolol—Nausea—Carmustine—melanoma	0.000215	0.00235	CcSEcCtD
Propranolol—Insomnia—Docetaxel—melanoma	0.00021	0.0023	CcSEcCtD
Propranolol—Paraesthesia—Docetaxel—melanoma	0.000208	0.00228	CcSEcCtD
Propranolol—Nausea—Temozolomide—melanoma	0.000207	0.00227	CcSEcCtD
Propranolol—Dyspnoea—Docetaxel—melanoma	0.000207	0.00227	CcSEcCtD
Propranolol—Somnolence—Docetaxel—melanoma	0.000206	0.00226	CcSEcCtD
Propranolol—Dyspepsia—Docetaxel—melanoma	0.000204	0.00224	CcSEcCtD
Propranolol—Acebutolol—ABCB1—melanoma	0.000204	0.0854	CrCbGaD
Propranolol—Decreased appetite—Docetaxel—melanoma	0.000202	0.00221	CcSEcCtD
Propranolol—Gastrointestinal disorder—Docetaxel—melanoma	0.0002	0.00219	CcSEcCtD
Propranolol—Fatigue—Docetaxel—melanoma	0.0002	0.00219	CcSEcCtD
Propranolol—Pain—Docetaxel—melanoma	0.000199	0.00217	CcSEcCtD
Propranolol—Constipation—Docetaxel—melanoma	0.000199	0.00217	CcSEcCtD
Propranolol—Gastrointestinal pain—Docetaxel—melanoma	0.00019	0.00208	CcSEcCtD
Propranolol—Body temperature increased—Docetaxel—melanoma	0.000184	0.00201	CcSEcCtD
Propranolol—Abdominal pain—Docetaxel—melanoma	0.000184	0.00201	CcSEcCtD
Propranolol—Metoprolol—ABCB1—melanoma	0.000172	0.0721	CrCbGaD
Propranolol—Hypersensitivity—Docetaxel—melanoma	0.000171	0.00187	CcSEcCtD
Propranolol—Asthenia—Docetaxel—melanoma	0.000167	0.00182	CcSEcCtD
Propranolol—Diarrhoea—Docetaxel—melanoma	0.000159	0.00174	CcSEcCtD
Propranolol—Dizziness—Docetaxel—melanoma	0.000154	0.00168	CcSEcCtD
Propranolol—Vomiting—Docetaxel—melanoma	0.000148	0.00162	CcSEcCtD
Propranolol—Rash—Docetaxel—melanoma	0.000146	0.0016	CcSEcCtD
Propranolol—Dermatitis—Docetaxel—melanoma	0.000146	0.0016	CcSEcCtD
Propranolol—Nausea—Docetaxel—melanoma	0.000138	0.00151	CcSEcCtD
Propranolol—Propafenone—ABCB1—melanoma	0.000127	0.0531	CrCbGaD
Propranolol—Carvedilol—ABCB1—melanoma	0.000114	0.0478	CrCbGaD
Propranolol—CYP1A2—Metabolism—SLC5A5—melanoma	6.3e-06	7.02e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CDKN1B—melanoma	6.3e-06	7.02e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—BRAF—melanoma	6.27e-06	6.99e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IGF1—melanoma	6.25e-06	6.96e-05	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—AKT1—melanoma	6.23e-06	6.94e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—MAPK1—melanoma	6.22e-06	6.93e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—EGFR—melanoma	6.22e-06	6.93e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CASP3—melanoma	6.17e-06	6.88e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MAP2K1—melanoma	6.17e-06	6.88e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ABCB1—melanoma	6.16e-06	6.87e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IL2—melanoma	6.16e-06	6.87e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—IL6—melanoma	6.13e-06	6.83e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CD—melanoma	6.13e-06	6.83e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IGF1—melanoma	6.11e-06	6.81e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CB—melanoma	6.09e-06	6.79e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GNAQ—melanoma	6.08e-06	6.78e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CD44—melanoma	6.08e-06	6.78e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CB—melanoma	6.08e-06	6.78e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—MAPK1—melanoma	6.08e-06	6.78e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—EGFR—melanoma	6.08e-06	6.77e-05	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—PIK3CA—melanoma	6.07e-06	6.77e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MAP2K1—melanoma	6.04e-06	6.73e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTGS2—melanoma	6.04e-06	6.73e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTGS2—melanoma	6.03e-06	6.72e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCND1—melanoma	6.01e-06	6.7e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—KRAS—melanoma	6e-06	6.69e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CD—melanoma	6e-06	6.69e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—KRAS—melanoma	5.98e-06	6.66e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	5.96e-06	6.64e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CTNNB1—melanoma	5.95e-06	6.63e-05	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—PIK3CA—melanoma	5.94e-06	6.62e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAP2K1—melanoma	5.9e-06	6.58e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	5.9e-06	6.58e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—KRAS—melanoma	5.87e-06	6.55e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—FGF2—melanoma	5.87e-06	6.54e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CD—melanoma	5.87e-06	6.54e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MMP9—melanoma	5.83e-06	6.5e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP1B1—melanoma	5.83e-06	6.5e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CDKN1A—melanoma	5.81e-06	6.48e-05	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—PIK3CA—melanoma	5.81e-06	6.48e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PTEN—melanoma	5.8e-06	6.46e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NFKB1—melanoma	5.77e-06	6.43e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CG—melanoma	5.75e-06	6.41e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—FGF2—melanoma	5.74e-06	6.4e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—KRAS—melanoma	5.74e-06	6.4e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.69e-06	6.35e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PRKCA—melanoma	5.67e-06	6.32e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ABCB1—melanoma	5.67e-06	6.32e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—AKT1—melanoma	5.66e-06	6.31e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ERCC2—melanoma	5.63e-06	6.27e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—FGF2—melanoma	5.62e-06	6.26e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PPARG—melanoma	5.55e-06	6.18e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PRKCA—melanoma	5.54e-06	6.17e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—PIK3CA—melanoma	5.52e-06	6.15e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MDM2—melanoma	5.49e-06	6.12e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—ERCC2—melanoma	5.49e-06	6.12e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—PIK3CA—melanoma	5.49e-06	6.12e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CG—melanoma	5.43e-06	6.05e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—ERBB2—melanoma	5.42e-06	6.04e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—PIK3CA—melanoma	5.4e-06	6.01e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MDM2—melanoma	5.37e-06	5.99e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP17A1—melanoma	5.35e-06	5.96e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CB—melanoma	5.34e-06	5.96e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TP53—melanoma	5.31e-06	5.92e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—ERBB2—melanoma	5.3e-06	5.9e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—PIK3CA—melanoma	5.28e-06	5.88e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTEN—melanoma	5.26e-06	5.87e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTEN—melanoma	5.26e-06	5.86e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MDM2—melanoma	5.25e-06	5.86e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PPARG—melanoma	5.24e-06	5.84e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—VEGFA—melanoma	5.24e-06	5.84e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CB—melanoma	5.23e-06	5.83e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PRKCA—melanoma	5.22e-06	5.81e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—STAT3—melanoma	5.19e-06	5.78e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ERBB2—melanoma	5.18e-06	5.77e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ERCC2—melanoma	5.17e-06	5.77e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NRAS—melanoma	5.17e-06	5.77e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.15e-06	5.74e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CXCL8—melanoma	5.14e-06	5.72e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CB—melanoma	5.11e-06	5.7e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—HRAS—melanoma	5.1e-06	5.69e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—HRAS—melanoma	5.08e-06	5.66e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CD—melanoma	5.05e-06	5.63e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GNA11—melanoma	5.05e-06	5.63e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CXCL8—melanoma	5.02e-06	5.6e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CDKN1B—melanoma	5.02e-06	5.59e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—HRAS—melanoma	4.99e-06	5.56e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—ALB—melanoma	4.99e-06	5.56e-05	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—AKT1—melanoma	4.96e-06	5.53e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MAPK3—melanoma	4.96e-06	5.52e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—FASN—melanoma	4.94e-06	5.51e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CASP3—melanoma	4.92e-06	5.48e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CXCL8—melanoma	4.91e-06	5.48e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL2—melanoma	4.91e-06	5.47e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CDKN1B—melanoma	4.91e-06	5.47e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—IL6—melanoma	4.88e-06	5.44e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—HRAS—melanoma	4.88e-06	5.44e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IL6—melanoma	4.86e-06	5.42e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SLC5A5—melanoma	4.86e-06	5.42e-05	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—AKT1—melanoma	4.85e-06	5.41e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MYC—melanoma	4.82e-06	5.37e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CASP3—melanoma	4.81e-06	5.36e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ABCB1—melanoma	4.8e-06	5.35e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL2—melanoma	4.8e-06	5.35e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CDKN1B—melanoma	4.8e-06	5.35e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCND1—melanoma	4.79e-06	5.33e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—IL6—melanoma	4.78e-06	5.32e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CD—melanoma	4.77e-06	5.32e-05	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—AKT1—melanoma	4.75e-06	5.29e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CTNNB1—melanoma	4.74e-06	5.28e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MAPK1—melanoma	4.71e-06	5.25e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—EGFR—melanoma	4.71e-06	5.25e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—ALB—melanoma	4.71e-06	5.25e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CASP3—melanoma	4.7e-06	5.24e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL2—melanoma	4.7e-06	5.23e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GNAQ—melanoma	4.69e-06	5.23e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CD44—melanoma	4.69e-06	5.23e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCND1—melanoma	4.68e-06	5.22e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—IL6—melanoma	4.67e-06	5.21e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.66e-06	5.19e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MMP9—melanoma	4.65e-06	5.18e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CTNNB1—melanoma	4.64e-06	5.17e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CDKN1A—melanoma	4.63e-06	5.16e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PTEN—melanoma	4.62e-06	5.15e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NFKB1—melanoma	4.6e-06	5.12e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCND1—melanoma	4.58e-06	5.1e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MMP9—melanoma	4.54e-06	5.06e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CTNNB1—melanoma	4.53e-06	5.05e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CDKN1A—melanoma	4.53e-06	5.05e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PTEN—melanoma	4.52e-06	5.04e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—AKT1—melanoma	4.51e-06	5.02e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYP1B1—melanoma	4.5e-06	5.02e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NFKB1—melanoma	4.5e-06	5.01e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—AKT1—melanoma	4.48e-06	5e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—KRAS—melanoma	4.45e-06	4.96e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MMP9—melanoma	4.44e-06	4.95e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CG—melanoma	4.44e-06	4.95e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CDKN1A—melanoma	4.43e-06	4.93e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PRKCA—melanoma	4.42e-06	4.93e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PTEN—melanoma	4.42e-06	4.92e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—AKT1—melanoma	4.41e-06	4.91e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CB—melanoma	4.4e-06	4.91e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NFKB1—melanoma	4.4e-06	4.9e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ERCC2—melanoma	4.38e-06	4.89e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTGS2—melanoma	4.36e-06	4.86e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CG—melanoma	4.34e-06	4.83e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—AKT1—melanoma	4.31e-06	4.8e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PPARG—melanoma	4.29e-06	4.78e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PPARG—melanoma	4.19e-06	4.66e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—VEGFA—melanoma	4.17e-06	4.65e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CB—melanoma	4.16e-06	4.64e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—STAT3—melanoma	4.13e-06	4.6e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTGS2—melanoma	4.12e-06	4.59e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NRAS—melanoma	4.12e-06	4.59e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PIK3CA—melanoma	4.09e-06	4.56e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CG—melanoma	4.09e-06	4.55e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—VEGFA—melanoma	4.08e-06	4.55e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—STAT3—melanoma	4.04e-06	4.5e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NRAS—melanoma	4.03e-06	4.49e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—VEGFA—melanoma	3.99e-06	4.45e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TP53—melanoma	3.96e-06	4.41e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—STAT3—melanoma	3.95e-06	4.4e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MAPK3—melanoma	3.95e-06	4.4e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PPARG—melanoma	3.94e-06	4.4e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NRAS—melanoma	3.94e-06	4.39e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CD—melanoma	3.91e-06	4.35e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MAPK3—melanoma	3.86e-06	4.3e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ALB—melanoma	3.86e-06	4.3e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MYC—melanoma	3.84e-06	4.28e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CD—melanoma	3.81e-06	4.25e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTEN—melanoma	3.81e-06	4.24e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—HRAS—melanoma	3.79e-06	4.22e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAPK3—melanoma	3.77e-06	4.21e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—ALB—melanoma	3.76e-06	4.19e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MAPK1—melanoma	3.75e-06	4.18e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MYC—melanoma	3.75e-06	4.18e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—EGFR—melanoma	3.75e-06	4.18e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CA—melanoma	3.71e-06	4.14e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CA—melanoma	3.71e-06	4.13e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ABCB1—melanoma	3.71e-06	4.13e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MAPK1—melanoma	3.67e-06	4.09e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—EGFR—melanoma	3.67e-06	4.09e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MYC—melanoma	3.67e-06	4.09e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.63e-06	4.05e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IL6—melanoma	3.62e-06	4.04e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTEN—melanoma	3.6e-06	4.01e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CD—melanoma	3.59e-06	4e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAPK1—melanoma	3.59e-06	4e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—EGFR—melanoma	3.59e-06	4e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KRAS—melanoma	3.55e-06	3.95e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ALB—melanoma	3.55e-06	3.95e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KRAS—melanoma	3.47e-06	3.87e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CG—melanoma	3.46e-06	3.86e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PRKCA—melanoma	3.41e-06	3.8e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CB—melanoma	3.4e-06	3.79e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KRAS—melanoma	3.39e-06	3.78e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ERCC2—melanoma	3.38e-06	3.77e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTGS2—melanoma	3.37e-06	3.76e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—AKT1—melanoma	3.34e-06	3.72e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PPARG—melanoma	3.34e-06	3.72e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CB—melanoma	3.32e-06	3.7e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTGS2—melanoma	3.29e-06	3.67e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CA—melanoma	3.26e-06	3.63e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CA—melanoma	3.19e-06	3.55e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TP53—melanoma	3.15e-06	3.51e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CB—melanoma	3.13e-06	3.49e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CA—melanoma	3.12e-06	3.47e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTGS2—melanoma	3.1e-06	3.46e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TP53—melanoma	3.08e-06	3.44e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CD—melanoma	3.04e-06	3.39e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—AKT1—melanoma	3.03e-06	3.38e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—AKT1—melanoma	3.03e-06	3.38e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TP53—melanoma	3.01e-06	3.36e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—HRAS—melanoma	3.01e-06	3.36e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ALB—melanoma	3e-06	3.35e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—HRAS—melanoma	2.95e-06	3.29e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTEN—melanoma	2.94e-06	3.28e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL6—melanoma	2.89e-06	3.22e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—HRAS—melanoma	2.88e-06	3.21e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTEN—melanoma	2.87e-06	3.2e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL6—melanoma	2.82e-06	3.15e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL6—melanoma	2.76e-06	3.08e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTEN—melanoma	2.71e-06	3.02e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CA—melanoma	2.68e-06	2.99e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CG—melanoma	2.67e-06	2.98e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—AKT1—melanoma	2.66e-06	2.97e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CB—melanoma	2.65e-06	2.96e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTGS2—melanoma	2.63e-06	2.93e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—AKT1—melanoma	2.6e-06	2.9e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PPARG—melanoma	2.58e-06	2.87e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—AKT1—melanoma	2.55e-06	2.84e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CA—melanoma	2.54e-06	2.83e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CD—melanoma	2.35e-06	2.62e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ALB—melanoma	2.32e-06	2.58e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTEN—melanoma	2.29e-06	2.55e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—AKT1—melanoma	2.19e-06	2.44e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CA—melanoma	2.08e-06	2.31e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—AKT1—melanoma	2.07e-06	2.31e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CB—melanoma	2.05e-06	2.28e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTGS2—melanoma	2.03e-06	2.26e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CA—melanoma	2.03e-06	2.26e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CA—melanoma	1.91e-06	2.13e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTEN—melanoma	1.77e-06	1.97e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AKT1—melanoma	1.7e-06	1.89e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AKT1—melanoma	1.65e-06	1.84e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CA—melanoma	1.62e-06	1.8e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AKT1—melanoma	1.56e-06	1.74e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AKT1—melanoma	1.32e-06	1.47e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CA—melanoma	1.25e-06	1.39e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKT1—melanoma	1.02e-06	1.14e-05	CbGpPWpGaD
